Novartis Financials
| NVSEF Stock | USD 98.25 6.75 6.43% |
Novartis |
Understanding current and past Novartis Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Novartis' financial statements are interrelated, with each one affecting the others. For example, an increase in Novartis' assets may result in an increase in income on the income statement.
Novartis Stock Summary
Novartis competes with Ono Pharmaceutical, GSK Plc, Grifols SA, Pfizer, and IONQ. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 104323 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | CH0012005267 |
| Business Address | Lichtstrasse 35, Basel, |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Benchmark | Dow Jones Industrial |
| Website | www.novartis.com |
| Phone | 41 61 324 1111 |
| Currency | USD - US Dollar |
Novartis Key Financial Ratios
There are many critical financial ratios that Novartis' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Novartis AG reports annually and quarterly.| Return On Equity | 0.11 | |||
| Return On Asset | 0.0645 | |||
| Beta | 0.47 | |||
| Z Score | 5.4 | |||
| Last Dividend Paid | 3.46 |
Novartis Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Novartis's current stock value. Our valuation model uses many indicators to compare Novartis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novartis competition to find correlations between indicators driving Novartis's intrinsic value. More Info.Novartis AG is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.59 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Novartis AG is roughly 1.69 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novartis' earnings, one of the primary drivers of an investment's value.Novartis AG Systematic Risk
Novartis' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Novartis volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Novartis AG correlated with the market. If Beta is less than 0 Novartis generally moves in the opposite direction as compared to the market. If Novartis Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Novartis AG is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Novartis is generally in the same direction as the market. If Beta > 1 Novartis moves generally in the same direction as, but more than the movement of the benchmark.
Novartis November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Novartis help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Novartis AG. We use our internally-developed statistical techniques to arrive at the intrinsic value of Novartis AG based on widely used predictive technical indicators. In general, we focus on analyzing Novartis Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Novartis's daily price indicators and compare them against related drivers.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 11.25 | |||
| Value At Risk | (3.80) | |||
| Potential Upside | 3.46 |
Complementary Tools for Novartis Pink Sheet analysis
When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |